1. Up Front

   Up Front 18 March 2024 Pages: 761 - 762

   

2. Feasibility of prevention of type 2 diabetes in low- and middle-income countries

   • Andre P. Kengne
   • Ambady Ramachandran

   Review Open access 15 February 2024 Pages: 763 - 772

   

3. Keeping pace: the primary cilium as the conducting baton of the islet

   • Olof Idevall-Hagren
   • Ceren Incedal Nilsson
   • Gonzalo Sanchez

   Review Open access 14 February 2024 Pages: 773 - 782

   

4. Harnessing the power of proteomics in precision diabetes medicine

   • Nigel Kurgan
   • Jeppe Kjærgaard Larsen
   • Atul S. Deshmukh

   Review 12 February 2024 Pages: 783 - 797

   

5. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis

   • Milena Jancev
   • Tessa A. C. M. Vissers
   • Thomas T. van Sloten

   Article Open access 16 February 2024 Pages: 798 - 810

   

6. Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial

   • Heikki Hyöty
   • Susanna Kääriäinen
   • Miguel Sanjuan

   Article Open access 19 February 2024 Pages: 811 - 821

   

7. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

   • Pedro Cardoso
   • Katie G. Young
   • on behalf of the MASTERMIND consortium

   Article Open access 22 February 2024 Pages: 822 - 836

   

8. Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank

   • Qiao Jin
   • Eric S. H. Lau
   • on behalf of the Hong Kong Diabetes Biobank Study Group

   Article Open access 27 February 2024 Pages: 837 - 849

   

9. Elevated ITGA1 levels in type 2 diabetes: implications for cardiac function impairment

   • Mengqi Su
   • Yilin Hou
   • Cong Chen

   Article Open access 27 February 2024 Pages: 850 - 863

   

10. Child-to-adult body size change and risk of type 2 diabetes and cardiovascular disease

    • Germán D. Carrasquilla
    • Lars Ängquist
    • Ruth J. F. Loos

    Article Open access 12 December 2023 Pages: 864 - 873

    

11. Low birthweight and overweight during childhood and young adulthood and the risk of type 2 diabetes in men: a population-based cohort study

    • Jimmy Célind
    • Maria Bygdell
    • Jenny M. Kindblom

    Article Open access 22 February 2024 Pages: 874 - 884

    

12. An omics-based machine learning approach to predict diabetes progression: a RHAPSODY study

    • Roderick C. Slieker
    • Magnus Münch
    • Joline W. J. Beulens

    Article Open access 19 February 2024 Pages: 885 - 894

    

13. Metabolomic and genetic architecture of gestational diabetes subtypes

    • Kristen Lee
    • Alan Kuang
    • William L. Lowe Jr

    Article 17 February 2024 Pages: 895 - 907

    

14. Interferons are key cytokines acting on pancreatic islets in type 1 diabetes

    • Alexandra Coomans de Brachène
    • Maria Ines Alvelos
    • Decio L. Eizirik

    Extended Article 26 February 2024 Pages: 908 - 927

    

15. Glucose tolerance and insulin resistance/sensitivity associate with retinal layer characteristics: the LIFE-Adult-Study

    • Franziska G. Rauscher
    • Tobias Elze
    • Mengyu Wang

    Article Open access 02 March 2024 Pages: 928 - 939

    

16. A loss-of-function mutation in KCNJ11 causing sulfonylurea-sensitive diabetes in early adult life

    • Natascia Vedovato
    • Maria V. Salguero
    • Frances M. Ashcroft

    Article Open access 17 February 2024 Pages: 940 - 951

    

17. Should children with type 1 diabetes really receive statin treatment using the same criteria as for children with familial hypercholesterolaemia?

    • Rosa M. Sánchez-Hernández
    • Ana M. Wägner

    Letter 26 February 2024 Pages: 952 - 953

18. Critical comments regarding the assessment of quality of life and the clinical impact of the POWER2DM intervention

    • Frans Pouwer
    • Sonya Deschênes

    Letter 01 March 2024 Pages: 954 - 955

19. Critical comments regarding the assessment of quality of life and the clinical impact of the POWER2DM intervention. Reply to Pouwer F, Deschênes SS [letter]

    • Merel M. Ruissen
    • Ewout W. Steyerberg
    • Jacob K. Sont

    Letter 01 March 2024 Pages: 956 - 957

20. Correction to: Advances and challenges in measuring hepatic glucose uptake with FDG PET: implications for diabetes research

    • Jeremy Basset‑Sagarminaga
    • Tineke van de Weijer
    • Vera Schrauwen‑Hinderling

    Correction 23 February 2024 Pages: 958 - 958